Arrowhead Pharmaceuticals Announced Interim Results From A Phase 1/2A Clinical Study Of ARO-CFB, The Company's Investigational RNA Interference (RNAi) Therapeutic Targeting Complement Factor B Being Developed As A Potential Treatment For Complement...

Arrowhead Pharmaceuticals宣佈了對ARO-CFb的1/2A期臨床研究的中期結果，該公司正在開發的RNA干擾（RNAi）療法，目標是補充因子b，作爲潛在的補充療法...

Benzinga · 12/11 20:40

Arrowhead Pharmaceuticals Announced Interim Results From A Phase 1/2A Clinical Study Of ARO-CFB, The Company's Investigational RNA Interference (RNAi) Therapeutic Targeting Complement Factor B Being Developed As A Potential Treatment For Complement Mediated Diseases

Arrowhead Pharmaceuticals宣佈了針對ARO-CFb的1/2A期臨床研究的中期結果，該研究是針對補體因子b的研究性RNA干擾(RNAi)治療，正在開發作爲補體介導疾病的潛在治療方法。

譯文內容由第三人軟體翻譯。

以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。